Biohit Oyj - Changes board/management/auditors

Changes to Biohit Oyj’s management

Biohit Oyj
Stock exchance release
16 December 2011
11:50 A.M.



Semi Korpela, M.Sc. (Econ.), born 1970, was appointed President and CEO of
Biohit Group as of 15 December 2011. Previously, Korpela worked as the
Financial Director of Biohit Group from 2003 to 2006. After this, Korpela held
positions as Financial Director at CPS Color Group, Medisize Group and LDR
Group Oy. 


Tapani Tiusanen, PhD. (Physics), DipEMC (Marketing), born 1956, was appointed
the new Head of Operations and IT of Biohit Group as of 16 December 2011.
Previously, Tiusanen worked in several positions at Labsystems Oyj, Vaisala Oyj
and Kibron Inc. and for the last three years as Development Manager at Biohit
Group. 


Ulla Savelainen, B.Sc. Econ., born 1949, was appointed Head of Financials, HR
and Communications of Biohit Group as of 16 December 2011. Previously,
Savelainen worked as a Financial Administration Consultant in several listed
companies. From 2000 to 2005, Savelainen worked as the Financial Manager of
Sentera Oyj. 


Terhi Lampén, M.Sc. (Econ.), born 1973, was appointed Head of Sales and
Marketing of Biohit Group as of 16 December 2011. Previously, Lampén worked as
the Nordic Sales Manager of the Diagnostics business and from the beginning of
2011 onwards as the Marketing Manager. Before her career at Biohit, Lampén
worked as a Product Specialist at Johnson & Johnson and as a Regional Manager
at Boehringer Ingelheim. 



Lea Paloheimo, PhD (Clinical Biochemistry), was appointed Head of Product
Development and Quality of Biohit Group as of 16 December 2011. Paloheimo has
worked at Biohit Group since 2001. Before her career at Biohit Group, Paloheimo
has worked as a Chemist at Huslab, a Sales Manager Dasico a/s in Denmark, a
Researcher at Orion Diagnostica (Orion Corporation) and a Chemist at the
Clinical Chemistry department of United Laboratories Ltd. She carried out her
PhD and postdoctoral research at the University of Copenhagen. 


For further details, contact:

Osmo Suovaniemi
MD, PhD, Professor
Chairman of the Board of Directors
Tel. +358 40 745 5605
osmo.suovaniemi@biohit.fi



Distribution:

NASDAQ

OMX Helsinki Oyj
Central Storage Facility (www.oam.fi)
Press
www.biohit.fi



About Biohit

Biohit Oyj is a globally operating Finnish biotechnology company established in
1988. Biohit's mission crystallises in its motto “Innovating for Health”. The
company assumes social responsibility by producing innovations, new
technologies and analysis systems for use in medicine, research institutions
and industry. These products help to promote research and diagnostics, while
improving quality of life by preventing disease, human suffering and financial
loss. Biohit also seeks to innovate and develop the marketing and availability
of its products and services, in order to ensure its profitable growth and
ability to pay dividends. 

Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations. These can be used to
develop safe and cost-effective diagnostic tests for the early detection and
prevention of diseases of the gastrointestinal tract. (www.biohit.fi /
International / State of the art GastroPanel and Acetium innovations for the
unmet need) 

Biohit's products include analysis systems for the prevention and early
diagnosis of gastrointestinal diseases, such as the blood-sample based
GastroPanel examinations for the diagnosis of stomach illnesses and associated
risks, quick tests for the diagnosis of lactose intolerance and H. pylori
infection in connection with gastroscopy, and the ColonView examination for the
early detection of intestinal bleeding that indicates a risk of colorectal
cancer. Acetium reduces the amount of carcinogenic acetaldehyde in an anacidic
stomach. (www.acetium.com/test - reveals acetaldehyde exposure) 

Biohit employs around 35 people. The company is headquartered in Helsinki,
Finland and has a subsidiary in the UK. Since 1999, Biohit's Series B share
(BIOBV) has been quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare
group and is traded under the code BIOBV (www.biohit.fi). 



Read more at www.biohit.fi